cotadutide solution for injection
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-alcoholic Steatohepatitis
Conditions
Non-alcoholic Steatohepatitis, Type 2 Diabetes Mellitus (T2DM), Chronic Kidney Disease
Trial Timeline
Mar 28, 2022 → Sep 12, 2022
NCT ID
NCT05294458About cotadutide solution for injection
cotadutide solution for injection is a phase 1 stage product being developed by AstraZeneca for Non-alcoholic Steatohepatitis. The current trial status is completed. This product is registered under clinical trial identifier NCT05294458. Target conditions include Non-alcoholic Steatohepatitis, Type 2 Diabetes Mellitus (T2DM), Chronic Kidney Disease.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05294458 | Phase 1 | Completed |
Competing Products
20 competing products in Non-alcoholic Steatohepatitis